« Return to News | Awards & Advancement

Plasticell honored at R&D 100 Awards

Wednesday, November 2, 2011 12:51 PM

For almost 50 years, the R&D 100 Awards have been recognizing the year’s best new high-technology products. Determined by a panel of experts chosen by R&D Magazine, the award is recognition that the selected product is one of the most important innovations of the year. Plasticell's CombiCult was chosen as one of the hundred for 2011, which included only three technologies from the U.K.

CombiCult was invented to solve the major bottleneck in stem cell research and development, and by extension, the bottleneck to regenerative drug discovery and cell therapy R&D. In its current iteration, the CombiCult workflow allows a single scientist to discover multiple methods of differentiating any stem cell to a mature cell-type of choice in weeks - the status quo takes a whole team of scientists years to discover perhaps a few non-optimal methods. CombiCult does this by effectively performing 10-100,000 experiments in parallel testing millions of combinations of differentiating factors in one go.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.